Allergan, Inc.

1159 articles with Allergan, Inc.

• Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference

  1/15/2021

  Allergan Aesthetics and Allergan, an AbbVie company (NYSE: ABBV), announced today that scientific and clinical experts in the field of neurotoxins will present results from 16 abstracts spanning pre-clinical and clinical studies evaluating key safety and efficacy of BOTOX® (onabotulinumtoxinA)

• Toronto Cosmetic Surgery Institute One of the First in Canada to Offer Newest Breast Implant by Allergan

  1/5/2021

  Patients exploring breast implants commonly search for ways to achieve the full look that still feels soft and natural to the touch, without rippling.

• Allergan, an AbbVie Company, Announces Positive Phase 3 Topline Results for Investigational AGN-190584 for the Treatment of Presbyopia

  10/28/2020

   Allergan, an AbbVie (NYSE: ABBV) company, today announced the Phase 3 GEMINI 1 and 2 clinical trials evaluating the efficacy, safety and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of symptoms associated with presbyopia, met their primary efficacy endpoint

• FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label for the Treatment of Pediatric Patients with Spasticity

  7/9/2020

  Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental Biologics License Application (sBLA) that supports expanded use of BOTOX® for the treatment of spasticity in pediatric patients 2 years of age and older, including those with lower limb spasticity caused by cerebral palsy.

• Allergan, an AbbVie Company, and Molecular Partners Receive Complete Response Letter from FDA on Biologics License Application for Abicipar pegol

  6/26/2020

  Allerganannounced that the U.S. Food and Drug Administration has issued a Complete Response Letter to the Biologics License Application for Abicipar pegol, a novel, investigational DARPin® therapy for patients with neovascular age-related macular degeneration.

• 

  Allergan/AbbVie's Macular Degeneration Drug Rejected by FDA

  6/26/2020

  The U.S. Food and Drug Administration issued a Complete Response Letter, a rejection, of Allergan’s Biologics License Application for Abicipar pegol for neovascular age-related macular degeneration.

• FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX® (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity

  6/22/2020

  Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental biologics license application (sBLA) to expand the BOTOX ® prescribing informati

• Allergan Aesthetics Launches Dedicated Multi-Channel Campaign To Contact Patients Who May Not Be Aware Of The BIOCELL® Recall And To Improve Tracking Information For U.S. Breast Implant Patients

  6/1/2020

  Connecting with patients to participate in device tracking enables them to be contacted in the event of a safety issue There is no additional safety information being communicated beyond the original July 2019 BIOCELL® recall   [01-June-2020]   IRVINE, Calif. , June 1, 2020 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is initiating a new di

• FDA issues warning letters to two breast implant manufacturers as part of ongoing efforts to protect patients

  5/14/2020

  Today, the U.S. Food and Drug Administration issued warning letters to two breast implant manufacturers for failure to comply with various regulatory requirements.

• AbbVie Completes Transformative Acquisition of Allergan

  5/8/2020

  AbbVie, a research-based global biopharmaceutical company, announced that it has completed its acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court.

• The Allergan Foundation Doubles its COVID-19 Response Donations to $4.0 Million

  5/7/2020

  - Total 2020 Charitable Grants to Date Approach $17 Million - - Lifetime Giving Approaches $112 Million -

• 

  One Step Closer: FTC Clears AbbVie and Allergan's $63 Billion Merger

  5/6/2020

  The U.S. Federal Trade Commission gave the green light to the $63 billion merger of AbbVie and Allergan. That leaves one last hurdle for the two companies, approval from the Irish High Court.

• AbbVie and Allergan Receive Clearance from U.S. Federal Trade Commission for AbbVie's Acquisition of Allergan

  5/5/2020

  AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the U.S. Federal Trade Commission (FTC) has accepted the proposed consent order in connection with AbbVie's pending acquisition of Allergan.

• AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes to May 8, 2020

  4/27/2020

  AbbVie Inc. announced the extension of the expiration date of the offers to exchange any and all outstanding notes of certain series issued by Allergan Finance, LLC, Allergan, Inc., Allergan Sales, LLC and Allergan Funding SCS for new notes to be issued by AbbVie and the related consent solicitations being made by AbbVie on behalf of Allergan to adopt certain amendments to each of the indentures governing the Allergan Notes.

• AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes to May 1, 2020

  4/20/2020

  AbbVie Inc. announced the extension of the expiration date of the offers to exchange any and all outstanding notes of certain series issued by Allergan Finance, LLC, Allergan, Inc., Allergan Sales, LLC and Allergan Funding SCS for new notes to be issued by AbbVie and the related consent solicitations being made by AbbVie on behalf of Allergan to adopt certain amendments to each of the indentures governing the Allergan Notes.

• China Gives Greenlight to Allergan's XEN® Registration for the Surgical Management of Refractory Glaucoma

  4/2/2020

  XEN® Becomes the First Medical Product Approved by Using Real World Evidence in China

• Allergan Earns ENERGY STAR® Partner of the Year - Sustained Excellence Award for the Seventh Consecutive Year

  3/31/2020

  Allergan plc (NYSE: AGN) today announced it has received the ENERGY STAR® Partner of the Year Sustained Excellence Award for 2020, marking the seventh consecutive year it has earned ENERGY STAR®'s highest honor.

• The Allergan Foundation Donates $2.0 Million to Community Organizations on Front-Line of COVID-19 Response

  3/30/2020

  - Total 2020 Charitable Grants to Date Approach $13 Million, Including More than $3 million Devoted to Mental Health -

• Allergan and Bausch Health Identified as the Top Companies Driving Therapeutic Innovation in IBS

  3/26/2020

  In an ongoing series of research conducted by KMK Consulting, Inc. covering Innovation & Customer Value, Allergan and Bausch Health (backed by its Salix division) were ranked as the top companies best poised to deliver therapeutic innovation in the IBS market. T

• 

  AbbVie and Allergan Sign Divestiture Consent Decree with FTC, Move Closer to Finalizing Merger

  3/18/2020

  The consent decree, including the proposed purchasers, remains subject to further review and approval by the Commissioners of the FTC.